Ultragenyx Pharmaceutical Inc. (RARE)
Automate Your Wheel Strategy on RARE
With Tiblio's Option Bot, you can configure your own wheel strategy including RARE - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol RARE
- Rev/Share 6.1346
- Book/Share 1.5708
- PB 24.7921
- Debt/Equity 0.2653
- CurrentRatio 2.3971
- ROIC -0.5005
- MktCap 3511289880.0
- FreeCF/Share -4.2896
- PFCF -8.5011
- PE -6.5071
- Debt/Assets 0.0292
- DivYield 0
- ROE -1.8649
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 4
- P/B Score 1
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | RARE | William Blair | -- | Outperform | -- | -- | May 28, 2025 |
News
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Published: June 20, 2025 by: GlobeNewsWire
Sentiment: Neutral
NOVATO, Calif., June 20, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of 48,731 restricted stock units of the company's common stock to 26 newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company's board of directors and granted under the Ultragenyx Employment Inducement Plan, with a grant date of June 16, 2025, as an inducement material to the new employees entering into employment with Ultragenyx in accordance with Nasdaq …
Read More
Ultragenyx (RARE) Up 9.6% Since Last Earnings Report: Can It Continue?
Published: June 05, 2025 by: Zacks Investment Research
Sentiment: Positive
Ultragenyx (RARE) reported earnings 30 days ago. What's next for the stock?
Read More
Ultragenyx to Participate at Bank of America's 2025 Healthcare Conference
Published: May 07, 2025 by: GlobeNewsWire
Sentiment: Neutral
NOVATO, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Howard Horn, the company's chief financial officer and executive vice president, will participate in a fireside at Bank of America's 2025 Healthcare Conference on Tuesday, May 13, 2025, at 8:00 a.m. PT.
Read More
Ultragenyx's Q1 Loss Wider Than Expected, Revenues Increase Y/Y
Published: May 07, 2025 by: Zacks Investment Research
Sentiment: Negative
RARE reports weaker-than-expected first-quarter results, as earnings and revenues miss estimates despite a year-over-year increase in product sales.
Read More
Ultragenyx (RARE) Reports Q1 Earnings: What Key Metrics Have to Say
Published: May 06, 2025 by: Zacks Investment Research
Sentiment: Positive
The headline numbers for Ultragenyx (RARE) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Read More
Ultragenyx (RARE) Reports Q1 Loss, Misses Revenue Estimates
Published: May 06, 2025 by: Zacks Investment Research
Sentiment: Negative
Ultragenyx (RARE) came out with a quarterly loss of $1.57 per share versus the Zacks Consensus Estimate of a loss of $1.54. This compares to loss of $2.03 per share a year ago.
Read More
5 Drug/Biotech Stocks Likely to Outperform Q1 Earnings Estimates
Published: May 05, 2025 by: Zacks Investment Research
Sentiment: Positive
Let us look at some drug/biotech stocks, NVO, PCRX, RARE, ACAD and DNLI, which are poised to beat on first-quarter 2025 earnings.
Read More
Ultragenyx: Commercial Engine Fuels Rare Disease Pipeline
Published: April 16, 2025 by: Seeking Alpha
Sentiment: Positive
Ultragenyx shows strong revenue growth and disciplined expense management, making it a compelling long-term investment despite inherent biotechnology risks. The company's diverse revenue streams from Crysvita, Dojolvi, and Evkeeza fund innovation and buffer against financial volatility. Key catalysts include the FDA's Priority Review of UX111 for Sanfilippo syndrome type A, with a PDUFA date set for August 2025.
Read More
Ultragenyx to Participate at Investor Conferences in March
Published: February 24, 2025 by: GlobeNewsWire
Sentiment: Neutral
NOVATO, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultrarare genetic diseases, today announced participation in three upcoming investor conferences.
Read More
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Published: February 19, 2025 by: GlobeNewsWire
Sentiment: Neutral
NOVATO, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultrarare diseases, today reported the grant of 23,760 restricted stock units of the company's common stock to 10 newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company's board of directors and granted under the Ultragenyx Employment Inducement Plan, with a grant date of February 16, 2025, as an inducement material to the new employees entering into employment with Ultragenyx in accordance with Nasdaq …
Read More
Ultragenyx Pharmaceutical Inc. (RARE) Q4 2024 Earnings Call Transcript
Published: February 13, 2025 by: Seeking Alpha
Sentiment: Neutral
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE ) Q4 2024 Earnings Conference Call February 13, 2025 5:00 PM ET Company Participants Joshua Higa - VP, IR Emil Kakkis - CEO and President Erik Harris - CCO Howard Horn - CFO Eric Crombez - CMO Conference Call Participants Tazeen Ahmad - Bank of America Salveen Richter - Goldman Sachs Gena Wang - Barclays Yaron Werber - TD Cowen Joon Lee - Truist Securities Jeff Hung - Morgan Stanley Rick Miller - Cantor Fitzgerald Luca Issi - RBC Capital Liisa Bayko - Evercore ISI Operator Good afternoon, and welcome to the Ultragenyx Fourth Quarter and …
Read More
Ultragenyx (RARE) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
Published: February 13, 2025 by: Zacks Investment Research
Sentiment: Positive
Although the revenue and EPS for Ultragenyx (RARE) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Read More
Ultragenyx Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Update
Published: February 13, 2025 by: GlobeNewsWire
Sentiment: Neutral
2024 Total Revenue of $560 million, exceeding guidance Crysvita® revenue of $410 million and Dojolvi® revenue of $88 million
Read More
About Ultragenyx Pharmaceutical Inc. (RARE)
- IPO Date 2014-01-31
- Website https://www.ultragenyx.com
- Industry Biotechnology
- CEO Dr. Emil D. Kakkis M.D., Ph.D.
- Employees 1294